Incyte Corp (NAS:INCY)
$ 69.91 0.07 (0.1%) Market Cap: 13.47 Bil Enterprise Value: 11.73 Bil PE Ratio: 499.36 PB Ratio: 4.25 GF Score: 89/100

Incyte Corp Data Highlights from ASH 2020 Transcript

Dec 07, 2020 / 03:00PM GMT
Release Date Price: $83.06 (-0.10%)
Michael Booth
Incyte Corporation - Divisional VP of IR & Corporate Social Responsibility

Good morning, and welcome to Incyte's highlights from ASH Conference Call and Webcast. The slides used today are available for download on the Investors section of incyte.com.

I'm joined on the call today by Steven Stein, our Chief Medical Officer; and by Peter Langmuir, Incyte's Group Vice President, Targeted Oncology Therapeutics; Herve and Christiana are also on the call and will participate as needed in the Q&A sessions.

We are also very pleased to be joined by Professor Robert Zeiser from the University of Freiburg in Germany, who will provide the important medical context for and a summary of the REACH3 results of ruxolitinib in chronic GVHD. There will be 2 Q&A sessions. (Operator Instructions)

Before we begin, I'd like to remind you that some of the statements made during the call today are forward-looking statements, including statements regarding the commercialization of our products, our development plans and expectations for the compounds in our pipeline as well as

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot